Oncology Approved Deal Benchmarks — Ex-US

Understanding Oncology Deal Benchmarks at Approved

Approved Oncology licensing deals in Ex-US territory command a median upfront payment of $934M, with values ranging from $693M at the low end to $1.2B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.2B to $2.9B, with a median of $2.5B. Royalty rates for oncology assets at this stage typically fall between 15.2% and 23.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.